Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK) has granted inducement equity awards to three new employees, comprising stock options for 27,429 shares and restricted stock units for 20,571 shares, totaling 48,000 shares of common stock. The awards are part of the company's 2022 Inducement Equity Plan, specifically designed for new hires.
The inducement stock options were priced at $42.60, matching the closing price on January 13, 2025. The vesting schedule includes 25% of shares vesting on the first employment anniversary, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments, contingent on continued employment.
Scholar Rock (NASDAQ: SRRK) ha concesso premi di equità come incentivo a tre nuovi dipendenti, consistenti in opzioni su azioni per 27.429 azioni e unità di azioni vincolate per 20.571 azioni, per un totale di 48.000 azioni ordinarie. I premi fanno parte del Piano di Equità da Incentivo 2022 dell'azienda, specificamente progettato per i nuovi assunti.
Le opzioni su azioni dell'inducement sono state fixate a $42,60, corrispondente al prezzo di chiusura del 13 gennaio 2025. Il piano di maturazione prevede il 25% delle azioni che matura al primo anniversario dell'impiego, con il restante 75% che matura in 12 rate trimestrali. Le unità di azioni vincolate matureranno in quattro rate annuali uguali, a condizione di un impiego continuato.
Scholar Rock (NASDAQ: SRRK) ha otorgado premios de equidad por inducimiento a tres nuevos empleados, que consisten en opciones sobre acciones para 27,429 acciones y unidades de acciones restringidas para 20,571 acciones, totalizando 48,000 acciones ordinarias. Los premios son parte del Plan de Equidad por Inducimiento 2022 de la compañía, diseñado específicamente para nuevos empleados.
Las opciones sobre acciones por inducimiento se fijaron en $42.60, coincidiendo con el precio de cierre del 13 de enero de 2025. El calendario de adquisición incluye el 25% de las acciones que se adquirirán en el primer aniversario del empleo, con el 75% restante adquiriéndose en 12 cuotas trimestrales. Las unidades de acciones restringidas se adquirirán en cuatro cuotas anuales iguales, condicionadas a la continuidad del empleo.
Scholar Rock (NASDAQ: SRRK)는 세 명의 새로운 직원에게 유인 지분 보상을 부여하였으며, 여기에는 27,429주에 대한 주식 옵션과 20,571주에 대한 제한된 주식 단위가 포함되어 총 48,000주의 보통주가 됩니다. 이 보상은 신입 사원을 위해 특별히 설계된 회사의 2022 유인 지분 계획의 일환입니다.
유인 주식 옵션의 가격은 $42.60으로, 2025년 1월 13일의 종가와 일치합니다. 취득 일정에는 첫 번째 고용 기념일에 25%의 주식이 취득되고, 나머지 75%는 12개의 분기별 할부로 취득됩니다. 제한된 주식 단위는 계속 고용되다는 조건으로 연간 4회 동일한 할부로 취득됩니다.
Scholar Rock (NASDAQ: SRRK) a accordé des primes d'équité d'incitation à trois nouveaux employés, comprenant des options d'achat d'actions pour 27 429 actions et des unités d'actions restreintes pour 20 571 actions, totalisant 48 000 actions ordinaires. Ces primes font partie du Plan d'Équité d'Incentive 2022 de l'entreprise, spécialement conçu pour les nouvelles recrues.
Les options d'actions d'incitation ont été fixées à $42.60, correspondant au cours de clôture du 13 janvier 2025. Le calendrier d'acquisition prévoit que 25% des actions seront acquises lors du premier anniversaire de l'emploi, le reste de 75% étant acquis en 12 versements trimestriels. Les unités d'actions restreintes seront acquises en quatre versements annuels égaux, sous réserve de la continuité de l'emploi.
Scholar Rock (NASDAQ: SRRK) hat drei neuen Mitarbeitern Anreiz-Aktienscheine gewährt, bestehend aus Aktienoptionen für 27.429 Aktien und beschränkten Aktieneinheiten für 20.571 Aktien, insgesamt 48.000 Stammaktien. Die Auszeichnungen sind Teil des Anreiz-Aktienplans 2022 des Unternehmens, der speziell für Neueinstellungen konzipiert wurde.
Die Anreiz-Aktienoptionen wurden zu einem Preis von $42,60 festgelegt, der dem Schlusskurs vom 13. Januar 2025 entspricht. Der Vesting-Zeitplan sieht vor, dass 25% der Aktien am ersten Arbeitsjubiläum vesten, während die verbleibenden 75% in 12 vierteljährlichen Raten vesten. Die beschränkten Aktieneinheiten werden in vier gleichen jährlichen Raten vesten, abhängig von der fortgesetzten Beschäftigung.
- Successful attraction of new talent with equity incentives
- Strong stock price at $42.60 per share
- Potential dilution of existing shareholders through new equity issuance
The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250117479655/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
Source: Scholar Rock
FAQ
What is the total value of Scholar Rock's (SRRK) January 2025 inducement grants?
What is the vesting schedule for SRRK's January 2025 inducement stock options?
How are Scholar Rock's (SRRK) 2025 inducement restricted stock units structured?
What was Scholar Rock's (SRRK) stock price when the inducement options were granted?
